A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma

Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9), an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. In preclinical models, MMP9 inhibitors have been shown to enhance the cytotoxic effects of chemotherapeutic agents and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ooki, Akira, Satoh, Taroh, Muro, Kei, Takashima, Atsuo, Kadowaki, Shigenori, Sakai, Daisuke, Ichimura, Takashi, Mitani, Seiichiro, Kudo, Toshihiro, Chin, Keisho, Kitano, Shigehisa, Thai, Dung, Zavodovskaya, Marianna, Liu, JieJane, Boku, Narikazu, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246925/
https://www.ncbi.nlm.nih.gov/pubmed/35773363
http://dx.doi.org/10.1038/s41598-022-13801-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246925/
https://www.ncbi.nlm.nih.gov/pubmed/35773363
http://dx.doi.org/10.1038/s41598-022-13801-1

Ejemplares similares